Company intelligence / Profile preview

Avekshan

Alachua, FL, United Statesavekshan.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Avekshan develops next-generation treatments for ADHD and other neuropsychiatric conditions. Its lead program, AVK001—a fixed-dose combination of methylphenidate and naltrexone—aims to reduce stimulant abuse potential while maintaining efficacy. The company also develops Norbinal as a non-narcotic alternative. Clinical results are not yet published; programs are advancing toward clinical trials via expedited regulatory pathways.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (e.g., methylphenidate, naltrexone)Fixed Dose CombinationsNon-narcotic therapeutics
Industry: Biotech

Drug pipeline

2 assets

Norbinal

Pre-clinical

Indications: ADHD, Major Depressive Disorder, Fragile X syndrome

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Avekshan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avekshan.

Explore the full profile